Dallas, Texas 01/13/2014 (FINANCIALSTRENDS) – Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) the US-based biopharmaceutical company which offers a line of top-range therapeutics for metabolic and cardiovascular diseases. It’s differentiator is the protein-based receptors it uses to develop these drugs. The company has a market capital of $1.39billion and volume of 7,240,462 and operates between 52-week high of $11 and 52-week low of $4.05
FTC drives crack down on weight-loss pills
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) remains unaffected by FTC-drive and higher regulatory requirements as it attempts to go solo on Belviq sales. In November competitor products such as Empatic were introduced by Orexigen. The concern is about one of the components ‘buproprion’ which is considered to be the cause of a range of CV risks in individuals using the drug.
Belviq to drive Arena revenues
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) will continue to push its Belviq weight-loss drug with a marketing tie-up with Eisai. Arena pharmaceuticals, in November announced marketing rights to Eisai to distribute Belviq across the world, with the exception of Taiwan, Israel, Australia as well as New Zealand. For Arena the benefit is $60 million as initial payment and graded payments to the tune of $176.56 million, up to $1.56 billion as single-time purchase.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has registered increase in sales across US and Canada, South America, China, Europe as well as Japan. The company expects to see a rise in the rates to as much as 35%, considering the sale in this area is expected to be over $500 million.
It also expects to see Belviq move to new market segments – due to cessation in smoking, options of once-daily formulation, besides fixed-dose combination where the key is phentermine besides a close look at how Belviq will impact the outcome when used where conditions of diabetes or cardiovascular conditions are prevalent.
The drive for more regulatory compliance for weight –loss formulations has just got stricter in the US and neighboring countries. However, the massive market-size off Asian markets will soon make up for sales numbers, if North American sales figures were to be affected, for Arena Pharmaceuticals.